357. OUTCOMES OF TWO-COURSE NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL ON ADVANCED ESOPHAGEAL CANCER: A SINGLE INSTITUTION STUDY Article Swipe
Masashi Hashimoto
,
Kazuhiro Noma
,
Kento Kawasaki
,
Tomoyoshi Kunitomo
,
Naoaki Maeda
,
Shunsuke Tanabe
,
Toshiyoshi Fujiwara
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/dote/doae057.116
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/dote/doae057.116
Background The CROSS trial established neoadjuvant chemoradiotherapy (CRT) as a cornerstone in treating esophageal cancer, making it the standard approach worldwide. However, in Japan, the JCOG1109 trial, a three-arm study, redefined the standard by showing the superiority of neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5-fluorouracil (DCF) over the conventional cisplatin and 5-fluorouracil (CF) regimen. Notably, it found no significant difference between neoadjuvant CRT with CF and CF. This trial adopted a 3-week cycle of 3 courses for the DCF regimen. Nonetheless, subsequent findings by Makino et al. suggested no difference in outcomes between 2-course and 3-course DCF regimens. This report presents the results of a 2-course neoadjuvant DCF regimen at our institution. Method This study included esophageal cancer patients who underwent esophagectomy after a 2-course NAC-DCF regimen at Okayama University Hospital from January 2014 to December 2019. Eligible participants were 20 to 80 years old, with a performance status of 0–1, histologically confirmed esophageal squamous cell carcinoma (ESCC), and adequate organ function. The stages ranged from cT1-4a N0-3 M0. We evaluated recurrence patterns, overall survival (OS), and recurrence-free survival (RFS) using the Kaplan-Meier method and explored histopathological factors associated with RFS through COX regression analysis. Results Out of 209 cases, 63 were eligible. The median follow-up was 71 months, with 17 instances of recurrence observed, categorized as lymphatic (6 cases), hematinic (3 cases), local (2 cases), dissemination (2 cases), and multiple (4 cases). The 5-year RFS was 64.5%, and the 5-year OS was 65.8%. Univariate analysis identified pathological T, N, Stage, and chemotherapy response grade as significant factors related to RFS, with multivariate analysis highlighting pathological N as an independent factor. Kaplan-Meier analysis demonstrated significant survival differences across N stages, particularly between N1 and N2. Conclusion Our findings from the 2-course neoadjuvant DCF regimen highlight pathological N stage as a crucial independent predictor of recurrence in ESCC patients treated with NAC-DCF. Specifically, patients above N2 exhibited notably poorer prognoses, underscoring the need for adjuvant treatment strategies.
Related Topics
Concepts
Medicine
Docetaxel
Cisplatin
Fluorouracil
Esophageal cancer
Oncology
Internal medicine
Chemotherapy
Neoadjuvant therapy
Cancer
Breast cancer
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/dote/doae057.116
- https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4402139175
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4402139175Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/dote/doae057.116Digital Object Identifier
- Title
-
357. OUTCOMES OF TWO-COURSE NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL ON ADVANCED ESOPHAGEAL CANCER: A SINGLE INSTITUTION STUDYWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-09-01Full publication date if available
- Authors
-
Masashi Hashimoto, Kazuhiro Noma, Kento Kawasaki, Tomoyoshi Kunitomo, Naoaki Maeda, Shunsuke Tanabe, Toshiyoshi FujiwaraList of authors in order
- Landing page
-
https://doi.org/10.1093/dote/doae057.116Publisher landing page
- PDF URL
-
https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdfDirect OA link when available
- Concepts
-
Medicine, Docetaxel, Cisplatin, Fluorouracil, Esophageal cancer, Oncology, Internal medicine, Chemotherapy, Neoadjuvant therapy, Cancer, Breast cancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4402139175 |
|---|---|
| doi | https://doi.org/10.1093/dote/doae057.116 |
| ids.doi | https://doi.org/10.1093/dote/doae057.116 |
| ids.openalex | https://openalex.org/W4402139175 |
| fwci | 0.0 |
| type | article |
| title | 357. OUTCOMES OF TWO-COURSE NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL ON ADVANCED ESOPHAGEAL CANCER: A SINGLE INSTITUTION STUDY |
| biblio.issue | Supplement_1 |
| biblio.volume | 37 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10619 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9990000128746033 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Esophageal Cancer Research and Treatment |
| topics[1].id | https://openalex.org/T10696 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9970999956130981 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Gastric Cancer Management and Outcomes |
| topics[2].id | https://openalex.org/T10417 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9912999868392944 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Lung Cancer Treatments and Mutations |
| is_xpac | False |
| apc_list.value | 3766 |
| apc_list.currency | USD |
| apc_list.value_usd | 3766 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9547513723373413 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2781190966 |
| concepts[1].level | 3 |
| concepts[1].score | 0.872786819934845 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q420436 |
| concepts[1].display_name | Docetaxel |
| concepts[2].id | https://openalex.org/C2778239845 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7624204158782959 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q412415 |
| concepts[2].display_name | Cisplatin |
| concepts[3].id | https://openalex.org/C2780456651 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6584056615829468 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q238512 |
| concepts[3].display_name | Fluorouracil |
| concepts[4].id | https://openalex.org/C2779742542 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6568560600280762 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q372701 |
| concepts[4].display_name | Esophageal cancer |
| concepts[5].id | https://openalex.org/C143998085 |
| concepts[5].level | 1 |
| concepts[5].score | 0.640863299369812 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[5].display_name | Oncology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.561345636844635 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C2776694085 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5043493509292603 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[7].display_name | Chemotherapy |
| concepts[8].id | https://openalex.org/C2778292576 |
| concepts[8].level | 4 |
| concepts[8].score | 0.48081934452056885 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q6991934 |
| concepts[8].display_name | Neoadjuvant therapy |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3514249920845032 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| concepts[10].id | https://openalex.org/C530470458 |
| concepts[10].level | 3 |
| concepts[10].score | 0.07624641060829163 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[10].display_name | Breast cancer |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9547513723373413 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/docetaxel |
| keywords[1].score | 0.872786819934845 |
| keywords[1].display_name | Docetaxel |
| keywords[2].id | https://openalex.org/keywords/cisplatin |
| keywords[2].score | 0.7624204158782959 |
| keywords[2].display_name | Cisplatin |
| keywords[3].id | https://openalex.org/keywords/fluorouracil |
| keywords[3].score | 0.6584056615829468 |
| keywords[3].display_name | Fluorouracil |
| keywords[4].id | https://openalex.org/keywords/esophageal-cancer |
| keywords[4].score | 0.6568560600280762 |
| keywords[4].display_name | Esophageal cancer |
| keywords[5].id | https://openalex.org/keywords/oncology |
| keywords[5].score | 0.640863299369812 |
| keywords[5].display_name | Oncology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.561345636844635 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/chemotherapy |
| keywords[7].score | 0.5043493509292603 |
| keywords[7].display_name | Chemotherapy |
| keywords[8].id | https://openalex.org/keywords/neoadjuvant-therapy |
| keywords[8].score | 0.48081934452056885 |
| keywords[8].display_name | Neoadjuvant therapy |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.3514249920845032 |
| keywords[9].display_name | Cancer |
| keywords[10].id | https://openalex.org/keywords/breast-cancer |
| keywords[10].score | 0.07624641060829163 |
| keywords[10].display_name | Breast cancer |
| language | en |
| locations[0].id | doi:10.1093/dote/doae057.116 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S170171939 |
| locations[0].source.issn | 1120-8694, 1442-2050 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1120-8694 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Diseases of the Esophagus |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Diseases of the Esophagus |
| locations[0].landing_page_url | https://doi.org/10.1093/dote/doae057.116 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5044730038 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-0329-5110 |
| authorships[0].author.display_name | Masashi Hashimoto |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[0].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I163770644 |
| authorships[0].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Okayama University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Masashi Hashimoto |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[1].author.id | https://openalex.org/A5076268036 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5584-3908 |
| authorships[1].author.display_name | Kazuhiro Noma |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[1].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I163770644 |
| authorships[1].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Okayama University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kazuhiro Noma |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[2].author.id | https://openalex.org/A5073536333 |
| authorships[2].author.orcid | https://orcid.org/0009-0006-7547-5926 |
| authorships[2].author.display_name | Kento Kawasaki |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[2].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I163770644 |
| authorships[2].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Okayama University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kento Kawasaki |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[3].author.id | https://openalex.org/A5052271348 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Tomoyoshi Kunitomo |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[3].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I163770644 |
| authorships[3].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Okayama University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Tomoyoshi Kunitomo |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[4].author.id | https://openalex.org/A5103819594 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Naoaki Maeda |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[4].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I163770644 |
| authorships[4].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Okayama University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Naoaki Maeda |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[5].author.id | https://openalex.org/A5110967778 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Shunsuke Tanabe |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[5].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I163770644 |
| authorships[5].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Okayama University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Shunsuke Tanabe |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| authorships[6].author.id | https://openalex.org/A5068717107 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-5377-6051 |
| authorships[6].author.display_name | Toshiyoshi Fujiwara |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I163770644 |
| authorships[6].affiliations[0].raw_affiliation_string | Okayama University , Kitaku, Okayama, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I163770644 |
| authorships[6].institutions[0].ror | https://ror.org/02pc6pc55 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I163770644 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Okayama University |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Toshiyoshi Fujiwara |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Okayama University , Kitaku, Okayama, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 357. OUTCOMES OF TWO-COURSE NEOADJUVANT CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL ON ADVANCED ESOPHAGEAL CANCER: A SINGLE INSTITUTION STUDY |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10619 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9990000128746033 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Esophageal Cancer Research and Treatment |
| related_works | https://openalex.org/W2428511172, https://openalex.org/W2052447841, https://openalex.org/W3004241701, https://openalex.org/W2921693759, https://openalex.org/W1584204846, https://openalex.org/W1622562614, https://openalex.org/W2285430064, https://openalex.org/W2361603891, https://openalex.org/W146255309, https://openalex.org/W1975533903 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/dote/doae057.116 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S170171939 |
| best_oa_location.source.issn | 1120-8694, 1442-2050 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1120-8694 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Diseases of the Esophagus |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Diseases of the Esophagus |
| best_oa_location.landing_page_url | https://doi.org/10.1093/dote/doae057.116 |
| primary_location.id | doi:10.1093/dote/doae057.116 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S170171939 |
| primary_location.source.issn | 1120-8694, 1442-2050 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1120-8694 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Diseases of the Esophagus |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/dote/article-pdf/37/Supplement_1/doae057.116/58989834/doae057.116.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Diseases of the Esophagus |
| primary_location.landing_page_url | https://doi.org/10.1093/dote/doae057.116 |
| publication_date | 2024-09-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.3 | 76 |
| abstract_inverted_index.N | 268, 280, 298 |
| abstract_inverted_index.a | 10, 28, 72, 106, 125, 148, 301 |
| abstract_inverted_index.(2 | 226, 229 |
| abstract_inverted_index.(3 | 223 |
| abstract_inverted_index.(4 | 233 |
| abstract_inverted_index.(6 | 220 |
| abstract_inverted_index.17 | 212 |
| abstract_inverted_index.20 | 142 |
| abstract_inverted_index.63 | 202 |
| abstract_inverted_index.71 | 209 |
| abstract_inverted_index.80 | 144 |
| abstract_inverted_index.CF | 66 |
| abstract_inverted_index.N, | 251 |
| abstract_inverted_index.N1 | 284 |
| abstract_inverted_index.N2 | 316 |
| abstract_inverted_index.OS | 243 |
| abstract_inverted_index.T, | 250 |
| abstract_inverted_index.We | 171 |
| abstract_inverted_index.an | 270 |
| abstract_inverted_index.as | 9, 218, 257, 269, 300 |
| abstract_inverted_index.at | 111, 129 |
| abstract_inverted_index.by | 34, 85 |
| abstract_inverted_index.et | 87 |
| abstract_inverted_index.in | 12, 23, 92, 307 |
| abstract_inverted_index.it | 17, 57 |
| abstract_inverted_index.no | 59, 90 |
| abstract_inverted_index.of | 38, 75, 105, 151, 199, 214, 305 |
| abstract_inverted_index.to | 136, 143, 261 |
| abstract_inverted_index.209 | 200 |
| abstract_inverted_index.CF. | 68 |
| abstract_inverted_index.COX | 194 |
| abstract_inverted_index.CRT | 64 |
| abstract_inverted_index.DCF | 80, 98, 109, 294 |
| abstract_inverted_index.M0. | 170 |
| abstract_inverted_index.N2. | 286 |
| abstract_inverted_index.Our | 288 |
| abstract_inverted_index.Out | 198 |
| abstract_inverted_index.RFS | 192, 237 |
| abstract_inverted_index.The | 2, 164, 205, 235 |
| abstract_inverted_index.al. | 88 |
| abstract_inverted_index.and | 45, 52, 67, 96, 160, 178, 186, 231, 240, 253, 285 |
| abstract_inverted_index.for | 78, 324 |
| abstract_inverted_index.our | 112 |
| abstract_inverted_index.the | 18, 25, 32, 36, 49, 79, 103, 183, 241, 291, 322 |
| abstract_inverted_index.was | 208, 238, 244 |
| abstract_inverted_index.who | 121 |
| abstract_inverted_index.(CF) | 54 |
| abstract_inverted_index.2014 | 135 |
| abstract_inverted_index.ESCC | 308 |
| abstract_inverted_index.N0-3 | 169 |
| abstract_inverted_index.RFS, | 262 |
| abstract_inverted_index.This | 69, 100, 115 |
| abstract_inverted_index.cell | 157 |
| abstract_inverted_index.from | 133, 167, 290 |
| abstract_inverted_index.need | 323 |
| abstract_inverted_index.old, | 146 |
| abstract_inverted_index.over | 48 |
| abstract_inverted_index.were | 141, 203 |
| abstract_inverted_index.with | 42, 65, 147, 191, 211, 263, 311 |
| abstract_inverted_index.(CRT) | 8 |
| abstract_inverted_index.(DCF) | 47 |
| abstract_inverted_index.(NAC) | 41 |
| abstract_inverted_index.(OS), | 177 |
| abstract_inverted_index.(RFS) | 181 |
| abstract_inverted_index.2019. | 138 |
| abstract_inverted_index.CROSS | 3 |
| abstract_inverted_index.above | 315 |
| abstract_inverted_index.after | 124 |
| abstract_inverted_index.cycle | 74 |
| abstract_inverted_index.found | 58 |
| abstract_inverted_index.grade | 256 |
| abstract_inverted_index.local | 225 |
| abstract_inverted_index.organ | 162 |
| abstract_inverted_index.stage | 299 |
| abstract_inverted_index.study | 116 |
| abstract_inverted_index.trial | 4, 70 |
| abstract_inverted_index.using | 182 |
| abstract_inverted_index.years | 145 |
| abstract_inverted_index.0–1, | 152 |
| abstract_inverted_index.3-week | 73 |
| abstract_inverted_index.5-year | 236, 242 |
| abstract_inverted_index.64.5%, | 239 |
| abstract_inverted_index.65.8%. | 245 |
| abstract_inverted_index.Japan, | 24 |
| abstract_inverted_index.Makino | 86 |
| abstract_inverted_index.Method | 114 |
| abstract_inverted_index.Stage, | 252 |
| abstract_inverted_index.across | 279 |
| abstract_inverted_index.cT1-4a | 168 |
| abstract_inverted_index.cancer | 119 |
| abstract_inverted_index.cases, | 201 |
| abstract_inverted_index.making | 16 |
| abstract_inverted_index.median | 206 |
| abstract_inverted_index.method | 185 |
| abstract_inverted_index.poorer | 319 |
| abstract_inverted_index.ranged | 166 |
| abstract_inverted_index.report | 101 |
| abstract_inverted_index.stages | 165 |
| abstract_inverted_index.status | 150 |
| abstract_inverted_index.study, | 30 |
| abstract_inverted_index.trial, | 27 |
| abstract_inverted_index.(ESCC), | 159 |
| abstract_inverted_index.January | 134 |
| abstract_inverted_index.NAC-DCF | 127 |
| abstract_inverted_index.Okayama | 130 |
| abstract_inverted_index.Results | 197 |
| abstract_inverted_index.adopted | 71 |
| abstract_inverted_index.between | 62, 94, 283 |
| abstract_inverted_index.cancer, | 15 |
| abstract_inverted_index.cases), | 221, 224, 227, 230 |
| abstract_inverted_index.cases). | 234 |
| abstract_inverted_index.courses | 77 |
| abstract_inverted_index.crucial | 302 |
| abstract_inverted_index.factor. | 272 |
| abstract_inverted_index.factors | 189, 259 |
| abstract_inverted_index.months, | 210 |
| abstract_inverted_index.notably | 318 |
| abstract_inverted_index.overall | 175 |
| abstract_inverted_index.regimen | 110, 128, 295 |
| abstract_inverted_index.related | 260 |
| abstract_inverted_index.results | 104 |
| abstract_inverted_index.showing | 35 |
| abstract_inverted_index.stages, | 281 |
| abstract_inverted_index.through | 193 |
| abstract_inverted_index.treated | 310 |
| abstract_inverted_index.2-course | 95, 107, 126, 292 |
| abstract_inverted_index.3-course | 97 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.December | 137 |
| abstract_inverted_index.Eligible | 139 |
| abstract_inverted_index.Hospital | 132 |
| abstract_inverted_index.However, | 22 |
| abstract_inverted_index.JCOG1109 | 26 |
| abstract_inverted_index.NAC-DCF. | 312 |
| abstract_inverted_index.Notably, | 56 |
| abstract_inverted_index.adequate | 161 |
| abstract_inverted_index.adjuvant | 325 |
| abstract_inverted_index.analysis | 247, 265, 274 |
| abstract_inverted_index.approach | 20 |
| abstract_inverted_index.explored | 187 |
| abstract_inverted_index.findings | 84, 289 |
| abstract_inverted_index.included | 117 |
| abstract_inverted_index.multiple | 232 |
| abstract_inverted_index.outcomes | 93 |
| abstract_inverted_index.patients | 120, 309, 314 |
| abstract_inverted_index.presents | 102 |
| abstract_inverted_index.regimen. | 55, 81 |
| abstract_inverted_index.response | 255 |
| abstract_inverted_index.squamous | 156 |
| abstract_inverted_index.standard | 19, 33 |
| abstract_inverted_index.survival | 176, 180, 277 |
| abstract_inverted_index.treating | 13 |
| abstract_inverted_index.analysis. | 196 |
| abstract_inverted_index.carcinoma | 158 |
| abstract_inverted_index.cisplatin | 51 |
| abstract_inverted_index.confirmed | 154 |
| abstract_inverted_index.eligible. | 204 |
| abstract_inverted_index.evaluated | 172 |
| abstract_inverted_index.exhibited | 317 |
| abstract_inverted_index.follow-up | 207 |
| abstract_inverted_index.function. | 163 |
| abstract_inverted_index.hematinic | 222 |
| abstract_inverted_index.highlight | 296 |
| abstract_inverted_index.instances | 213 |
| abstract_inverted_index.lymphatic | 219 |
| abstract_inverted_index.observed, | 216 |
| abstract_inverted_index.patterns, | 174 |
| abstract_inverted_index.predictor | 304 |
| abstract_inverted_index.redefined | 31 |
| abstract_inverted_index.regimens. | 99 |
| abstract_inverted_index.suggested | 89 |
| abstract_inverted_index.three-arm | 29 |
| abstract_inverted_index.treatment | 326 |
| abstract_inverted_index.underwent | 122 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 287 |
| abstract_inverted_index.Univariate | 246 |
| abstract_inverted_index.University | 131 |
| abstract_inverted_index.associated | 190 |
| abstract_inverted_index.cisplatin, | 44 |
| abstract_inverted_index.difference | 61, 91 |
| abstract_inverted_index.docetaxel, | 43 |
| abstract_inverted_index.esophageal | 14, 118, 155 |
| abstract_inverted_index.identified | 248 |
| abstract_inverted_index.prognoses, | 320 |
| abstract_inverted_index.recurrence | 173, 215, 306 |
| abstract_inverted_index.regression | 195 |
| abstract_inverted_index.subsequent | 83 |
| abstract_inverted_index.worldwide. | 21 |
| abstract_inverted_index.categorized | 217 |
| abstract_inverted_index.cornerstone | 11 |
| abstract_inverted_index.differences | 278 |
| abstract_inverted_index.established | 5 |
| abstract_inverted_index.independent | 271, 303 |
| abstract_inverted_index.neoadjuvant | 6, 39, 63, 108, 293 |
| abstract_inverted_index.performance | 149 |
| abstract_inverted_index.significant | 60, 258, 276 |
| abstract_inverted_index.strategies. | 327 |
| abstract_inverted_index.superiority | 37 |
| abstract_inverted_index.Kaplan-Meier | 184, 273 |
| abstract_inverted_index.Nonetheless, | 82 |
| abstract_inverted_index.chemotherapy | 40, 254 |
| abstract_inverted_index.conventional | 50 |
| abstract_inverted_index.demonstrated | 275 |
| abstract_inverted_index.highlighting | 266 |
| abstract_inverted_index.institution. | 113 |
| abstract_inverted_index.multivariate | 264 |
| abstract_inverted_index.participants | 140 |
| abstract_inverted_index.particularly | 282 |
| abstract_inverted_index.pathological | 249, 267, 297 |
| abstract_inverted_index.underscoring | 321 |
| abstract_inverted_index.Specifically, | 313 |
| abstract_inverted_index.dissemination | 228 |
| abstract_inverted_index.esophagectomy | 123 |
| abstract_inverted_index.5-fluorouracil | 46, 53 |
| abstract_inverted_index.histologically | 153 |
| abstract_inverted_index.recurrence-free | 179 |
| abstract_inverted_index.chemoradiotherapy | 7 |
| abstract_inverted_index.histopathological | 188 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6600000262260437 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.29684499 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |